T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...